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Abstract
Introduction: Despite the rising availability and use of medical marijuana (MM) in the USA, little is known about the demographics, clinical characteristics, or quality of life of MM
patients. This study describes the demographic characteristics and health-related quality of life (HRQoL) of MM patients
who are initiating treatment in Pennsylvania. Methods: Twohundred adults naive to MM and referred for any of the 23
state-approved qualifying conditions were recruited at three
MM dispensaries in Pennsylvania between September 2020
and March 2021. All participants consented to the study;
completed semi-structured interviews that included demographic questionnaires, the Short Form-36 (SF-36), and Generalized Anxiety Disorder-7 (GAD-7); provided height and
weight measurements; and allowed access their dispensary
medical records. Results: Participants had a mean age of
48.5 ± 15.6 years, predominantly identified as female (67.5%),
and were most commonly referred for chronic pain (63.5%)
and/or anxiety (58.5%). Additionally, 46.0% were living with
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obesity as determined by BMI. Relative to a normative sample, participants reported diminished HRQoL in several domains, most notably in role limitations due to physical health
(M = 46.0 ± 42.0), role limitations due to emotional problems
(M = 52.5 ± 42.3), energy and fatigue (M = 39.8 ± 20.2), and
pain (M = 49.4 ± 26.0). Discussion/Conclusion: Patients initiating MM treatment experienced low HRQoL in multiple domains. Future studies could evaluate the relationship between HRQoL and patients’ decisions to pursue MM treatment, as well as changes in HRQoL with MM use over time.
© 2022 The Author(s).
Published by S. Karger AG, Basel

Introduction

Medical marijuana (MM) is currently legal in 36 US
states and 4 territories [1] and is swiftly gaining traction
as a therapeutic option for a range of health concerns [1].
Federally, MM continues to be classified as a Schedule I
controlled substance [2], limiting the feasibility of conducting randomized controlled trials involving MM.
David S. Festinger is deceased.
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Table 1. Characteristics of adults
presenting for MM treatment at three
Pennsylvania dispensaries (N = 200)

Demographic variable
Age, years
Monthly income, USD
Weight, pounds
Height, inches
BMI, kg/m2
Underweight
Healthy weight
Overweight
Obese
Biological sex
Male
Female
Race
White
Black
Asian
American Indian
Alaska Native
Hawaiian/Pacific Islander
Mixed
Other
Ethnicity
Hispanic or Latinx
Non-Hispanic or Latinx
Education
Some high school
High school diploma or equivalent (GED)
Some college
Trade/technical/vocational training
Associate’s degree
Bachelor’s degree
Master’s degree
Doctorate
Marital status*
Single (never married)
Married
Domestic partnership
Separated
Divorced
Widowed
Living situation
With partner and children
With partner alone
With children alone
With parents
With family
With friends
Alone
Controlled environment
Employment status (past 3 years)
Full-time (40 h/week)
Part-time (regular hours)
Part-time (irregular hours)
Student
Retired/disability
Unemployed

Frequency

%

1
44
63
92

0.50
22.00
31.50
46.00

65
135

32.50
67.50

189
6
2
0
0
0
2
1

94.50
3.00
1.00
0
0
0
1.00
0.50

5
195

2.50
97.50

6
50
33
12
21
53
21
4

3.00
25.00
16.50
6.00
10.50
26.50
10.50
2.00

49
114
2
4
22
7

24.50
57.00
1.00
2.00
11.50
3.50

68
62
7
11
18
8
25
1

34.00
31.00
3.50
5.50
9.00
4.00
12.50
0.50

101
15
11
12
50
11

50.50
7.50
5.50
6.00
25.00
5.50

M

SD

48.55
2,650.10
189.81
66.39
30.18

15.60
2,386.80
50.21
3.88
7.15

* Marital status unknown for 2 participants.
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Without data from large, randomized clinical trials of
MM for the treatment of qualifying conditions (which
vary by state), there is little clarity regarding safety, efficacy, or appropriate dosing of MM for these conditions
[3, 4]. A review of MM clinical trials found the strongest
evidence to support its efficacy for the treatment of chronic pain, neuropathic pain, and spasticity associated with
multiple sclerosis [5]. Currently, there is a paucity of randomized, controlled trials supporting the efficacy of MM
for the treatment of post-traumatic stress disorder and
anxiety disorders [6, 7].
Despite the burgeoning availability and use of MM,
relatively little is known about the characteristics, healthrelated quality of life (HRQoL), and psychosocial functioning of MM patients. Studies of patients in Florida [8]
and California [9] reported chronic pain, anxiety, stress,
and insomnia to be the most common complaints or conditions prompting referrals for MM. Among chronic pain
patients in Ohio considering MM, 67.6% wanted to reduce their use of opioid medications, and 93.6% were
amenable to following physician recommendations regarding the use of opioids and MM concurrently [10].
Additionally, a study of patients seeking MM cards in
Michigan found lower self-perceptions of general health
in this population compared to adult respondents in a
statewide Behavioral Risk Factor Survey [11].
In 2016, Pennsylvania became the 24th US state to legalize MM, and the product is now available in a variety
of forms including pills, oil, tincture, and dry leaf for the
treatment of 23 medical conditions (Table 1) [12]. The
current observational study sought to describe the demographic and clinical characteristics, including HRQoL, of
patients initiating MM treatment for any of these approved conditions at three dispensaries in central Pennsylvania.
Materials and Methods
Inclusion/Exclusion Criteria
Patients were eligible to participate if they were 18 years of age
or older, prescribed MM for any approved medical condition, and
had not previously initiated MM treatment (i.e., this was their first
MM treatment episode). Patients who presented with cognitive
impairment that precluded informed consent, reported heavy recreational marijuana use, or were not English speaking were excluded from the study.

Table 2. Frequencies of MM referral reason and pharmacist
medication recommendation (N = 200)*
Condition

Total

%

Chronic pain
Anxiety
PTSD
Neuropathies
Cancer
IBS
Damage to nervous tissue
Multiple sclerosis
Glaucoma
Crohn’s disease
Parkinson’s disease
Dyskinetic disorder
Sickle cell anemia
Autism
ALS

127
117
16
11
12
12
6
5
3
2
2
1
1
1
1

63.50
58.50
8.00
5.50
6.00
6.00
3.00
2.50
1.50
1.00
1.00
0.50
0.50
0.50
0.50

* Participants may be referred for more than one condition.
PTSD, post-traumatic stress disorder.

sultations were conducted via phone, and patients who expressed
interest in the study were transferred to the on-site research staff.
Interested patients that met the eligibility criteria were invited for
a brief in-person meeting at the dispensary to complete the informed consent process and select assessments (i.e., cognitive assessments, height, and weight). The remaining baseline study measures were administered via phone within 1 week of the completion of informed consent. Participants who completed the baseline
assessment were remunerated 25 USD and offered a discount on
their MM purchases. In total, the baseline in-person and phone
appointments took approximately 60–90 min to complete. Of the
245 patients approached for study participation, 200 provided
consent and were enrolled (81.63%). The most common reasons
for declining to participate were not having time to complete study
activities and preferring to begin use of MM before the scheduled
date for the baseline assessment.
Measures
All survey and anthropometric measures were administered at
baseline for the current study.
Montreal Cognitive Assessment
The Montreal Cognitive Assessment (MoCA-B) screens for
cognitive impairment in six domains: visual perception, executive
functioning, language, attention, memory, and orientation [13].
The maximum score on the MoCA-B is 30 with lower scores indicating greater impairment and a cutoff of 26 considered normal
cognitive functioning.

Procedure
Participants were recruited between September 2020 and
March 2021 at three dispensary locations in central Pennsylvania.
Interested patients were introduced to research staff utilizing a
“warm handoff” from the dispensary pharmacist. Pharmacist con-

36-Item Short-Form Health Survey
The 36-Item Short-Form Health Survey (SF-36) is a structured
clinical interview assessing general health in terms of overall functioning and well-being [14]. The SF-36 measures HRQoL in eight
domains: physical functioning (limitations in performing daily ac-
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Table 3. Means and standard deviations for the SF-36 composite scales in the MM patients (N = 200) and MOS
participants (N = 2,471) [18, 19]
MM patients (N = 200)

Physical functioning
Role limitations due to physical health
Role limitations due to emotional problems
Energy/fatigue
Emotional well-being
Social functioning
Pain
General health

tivities due to physical health), role limitations due to physical
challenges (difficulties performing normal roles at work, school, or
home due to physical challenges), emotional well-being (general
mental health), role limitations due to emotional challenges (difficulties performing normal roles at work, school, or home due to
emotional challenges), social functioning (ability to socialize given
physical and/or mental health challenges), energy/fatigue (general
vitality), pain (current levels of bodily pain), and general health
(current perceptions of overall health). Lower scores indicate lower functioning in each domain.
The SF-36 is normed using data from adults in the Medical
Outcomes Study (MOS, Table 3). We felt comparison of our participants’ scores on HRQoL to MOS norms appropriately given
that the MOS study recruited patients with a high prevalence of
chronic health conditions and were seen in family medicine, general internal medicine, cardiology, or psychiatry/psychology in
health centers from four US census regions.
Problem Severity Rating
Participants reported the current severity of their primary referring condition on a scale ranging from 1 to 10, with 10 being the
most severe.
Generalized Anxiety Disorder-7 Item Scale
The Generalized Anxiety Disorder-7 Item Scale (GAD-7) [15]
is a seven-item scale assessing symptoms of anxiety and their impact on functioning in the past 2 weeks using a Likert-type scale.
Scores of 0, 1, 2, and 3 are assigned to four response categories,
indicating the frequency with which the participant experienced
symptoms. Scores on each question are then added together for a
total score between 0 and 21. Scores of 0–4, 5–9, 10–14, and 15–21
represent minimal, mild, moderate, and severe levels of anxiety,
respectively.
Anthropometric Measures
Research staff collected participants’ heights (in) and weights
(lbs.) (SECA 813; SECA Corp., Chino, CA, USA) with no shoes and
light clothing. BMI (kg/m2) was calculated using these measurements.
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MOS study patients [19]
(N = 2,471)

M

SD

M

SD

69.67
46.00
52.50
39.80
63.32
64.06
49.45
54.74

27.99
42.05
42.33
20.16
19.48
28.02
26.00
24.78

70.61
52.97
65.78
52.15
70.38
78.77
70.77
56.99

27.42
40.78
40.71
22.39
21.97
25.43
25.46
21.11

Demographic and Medical Information
Participants reported their biological sex at birth, identified
gender, age, marital status, race/ethnicity, education, socioeconomic status, medical diagnoses, and the medical reason for their
marijuana recommendation. Information from participants’ dispensary records, including referring condition, route of administration and MM products’ prescribed dose, and the frequency of
MM use, was also recorded.
Statistical Analyses
Descriptive statistics (e.g., means, standard deviations, and
percentages) were calculated to characterize the sample in terms of
demographic and clinical characteristics, functional status, and
HRQoL at treatment initiation.

Results

Demographic and Clinical Characteristics
Participants (N = 200) had a mean age of 48.5 ± 15.6
years, and the majority were female (67.5%), married
(57.0%), and White (94.5%) with an average monthly income of 2,650.1 ± 2,386.8 USD (Md = 2,000 USD). Participants’ mean BMI was 30.18 ± 7.15 kg/m2, and 46.0%
were living with obesity (Table 1). More than three-quarters of the sample (78%) reported no significant history
of recreational marijuana use. The most common methods of administration for MM were tincture (47%), topical (32.5%), and hybrid cartridge (31%). Additionally,
27% of participants endorsed currently using any prescribed psychotropic medication.
The most common reasons for MM referral were to
treat chronic pain (63.5%), anxiety (58.5%), and/or posttraumatic stress disorder (8.0%) (Table 2). Overall, participants endorsed moderate referral condition severity
ratings (6.78 ± 2.01).
Buonomano/Mitnick/McCalmont/
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HRQoL
Participants (N = 200) reported low levels of HRQoL
in multiple domains relative to normative data, most notably in role limitations due to physical health (46.0 ±
42.0), role limitations due to emotional problems (52.5 ±
42.3), energy and fatigue (39.8 ± 20.2), and pain (49.5 ±
26.0, Table 3). Participants presenting with only chronic
pain reported a mean pain score of 40.2 ± 20.7. Furthermore, participants also reported diminished HRQoL as
measured by the physical and mental composite scores
from the SF-36 (38.66 ± 19.95; 31.91 ± 20.96, respectively). SF-36 scores for the current sample of MM patients,
as well as patients with chronic conditions from the MOS,
are in Table 3 [12].

This study is among the first to describe the biopsychosocial profiles of patients presenting for MM treatment.
Several findings are noteworthy. First, the most common
referral conditions of participants in the sample were
chronic pain and anxiety, which is consistent with findings
from previous studies in this area [8, 9]. Collectively, our
findings suggest that patients with chronic pain or anxiety
may pursue alternative therapies for symptom relief beyond prescription medications or psychotherapy. It is possible that the addictive potential of certain prescription
medications for these particular disorders (e.g., benzodiazepines, opioids), the limited but growing evidence base
supporting the efficacy of MM for these conditions [5, 16,
17], and/or lack of symptom relief or resolution from other types of treatment may contribute to the decision to pursue MM in individuals living with chronic pain or anxiety.
Alternatively, physicians may be more willing to recommend MM for chronic pain and anxiety compared to oth-

er qualifying conditions. This trend could also be an artifact of the higher prevalence of these conditions when
compared to many of the other qualifying conditions in
Pennsylvania. Future studies including qualitative interviews with patients who have these conditions and/or their
referring health care providers could offer more clarity regarding decision-making related to initiating MM. Finally,
in our study, we utilized the SF-36 [14] to assess pain,
which asks respondents to both rate the severity of their
pain over the past 4 weeks, as well as how pain has interfered with their normal activities. While this SF-36 scale is
well-validated and widely used, future studies should consider utilizing more comprehensive pain measurements to
obtain a better understanding of pain levels and its impact
on functioning in MM patients.
In our study, 67.5% of participants in the current study
identified as female. This high rate of female study participation may be due to a number of factors. Prior research
suggests that females are more likely to be diagnosed with
chronic pain and anxiety disorders than males, and more
are likely to use MM [18–20]. In addition, females are more
likely to utilize other complementary and alternative medicines than males [21] and are less likely to report satisfactory pain relief from commonly prescribed pain medications [22].
It is important to note that 46.0% of this predominantly
White sample lived with obesity, which is approximately
7% higher than obesity rates reported in White adults in
the general US population (39.8%) [23]. The high rate of
chronic pain patients in our sample, who may experience
limited mobility [24], may have contributed to these elevated rates. Patients with chronic pain had significantly
higher rates of obesity (p = 0.038) when compared to the
rest of the sample. Nonetheless, changes in body weight
may be an important clinical factor to monitor as MM
treatment progresses, particularly in patients presenting
with obesity.
MM patients reported diminished HRQoL in several
areas when compared to patients with chronic health conditions in the MOS [12] and others [25]. Specifically, participants reported mean HRQoL pain scores that were 30%
lower (indicating reduced functioning due to pain), and
energy/fatigue scores that were 24% lower than the MOS
sample. They also reported notable limitations in physical
and emotional functioning, even relative to those observed
in another study of MM patients [25]. Given the perceived
improvements in anxiety associated with marijuana for
some users [26], future studies are needed to understand
the impact of MM treatment on HRQoL over time. Finally,
it is possible that the diminished HRQoL observed in this

Quality of Life in Medical Marijuana
Patients

Med Cannabis Cannabinoids 2022;5:95–101
DOI: 10.1159/000524831

Cognition
Participants’ (N = 197) mean MoCA score was 25.83 ±
3.57. Mean scores for the MoCA-B domains were as follows: executive functioning = 4.27, naming = 2.93, attention = 5.29, language = 2.38, abstraction = 1.67, delayed
recall = 3.47, and orientation = 5.88.
Anxiety
Participants (N = 200) reported mean GAD-7 scores
of 7.57 ± 5.50, indicating mild levels of anxiety. Average
GAD-7 scores in participants who presented with anxiety
as a referring condition were 9.53 ± 5.14, indicating mild
to moderate levels of anxiety.
Discussion/Conclusion

99

study may be attributed to the COVID-19 pandemic. In all,
these findings emphasize the need to further understand
the factors influencing baseline characteristics in patients
referred for MM.
Most participants’ cognitive functioning, as measured
by the MoCA, was within a normal range. The MoCA was
utilized previously as a screening tool for global cognitive
functioning impairment in patients with cancer using MM
compared to nonusers [27], and no significant differences
were found over the first 3 months of MM use. However,
cognitive impairment can be associated with several of the
qualifying conditions for MM (e.g., amyotrophic lateral
sclerosis, epilepsy, Huntington’s disease) or alternatively
can develop as a side effect of the traditional treatment of
them (e.g., «chemo brain»). Therefore, screening for cognitive impairment prior to MM initiation could help to identify patients that may require additional support to adhere
to their recommended MM regimen and, in turn, maximize the potential benefits of this therapeutic approach.
The current study had several strengths. First, well-validated measures examined patient characteristics and assessed functioning. Additionally, the high percentage of
eligible individuals recruited (81.63%) and large sample
size support the generalizability of our findings. The study
also had several limitations. This study was observational,
did not employ an experimental design, and did not examine changes in functioning over time. Although it is likely
that most patients engaging in MM treatment expect their
health-related functioning, including limitations related to
pain, to improve, it is plausible that the potential adverse
effects of regular use could also negatively impact various
domains of quality of life. Longitudinal studies that incorporate rigorous experimental designs would help to better
clarify potential positive or negative changes in functioning associated with MM use. Despite these limitations, the
current study furthers understanding of the biopsychosocial profiles of individuals initiating MM treatment in
Pennsylvania.
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